<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043977</url>
  </required_header>
  <id_info>
    <org_study_id>CL053</org_study_id>
    <nct_id>NCT02043977</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Propofol Infusion for Refractory Chronic Primary Insomnia</brief_title>
  <official_title>An Open Label, Pilot Study Utilizing an IV Infusion of Propofol in Male and Female Volunteers With Refractory Chronic Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Life Extension Foundation Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Life Extension Foundation Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insomnia is a widespread condition in which approximately one-third of adults in the United
      States are symptomatic with 6% of the population meeting the diagnostic criteria for
      insomnia. There is an increased risk of insomnia in certain segments of the population
      including women, middle-aged and older adults, shift workers and individuals with medical or
      psychiatric disorders. Individuals with insomnia have a decreased quality of life compared to
      those who report other serious illnesses such as major depression and congestive heart
      failure. Chronic insomnia can be caused by medications, drug or alcohol abuse, psychiatric
      disorders, medical and neurologic disorders. It can impair cognitive and physical
      functioning.

      Propofol is an approved drug administered intravenously for use in the induction and
      maintenance of anesthesia or sedation. Some research suggests that propofol when administered
      as a two hour infusion may improve the ease of sleep onset, sleep quality, ease of awakening
      and the integrity of behavior following waking.

      This study will be conducted in the Broward Health Medical Center Sleep Lab, under the direct
      care of a Board Certified Anesthesiologist, dedicated to the study involving participants who
      have refractory chronic primary insomnia and have not responded to conventional pharmacologic
      therapies within the past 90 days. Each qualifying participant will receive an IV infusion of
      the study medication for 5 consecutive nights. Assessments including polysomnography with
      completion of questionnaires will occur at screening, Days 1 through 5 of study product
      administration, Day 6 and Day 90. Follow-up questionnaires will also be distributed on Day
      180.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the scores on the subjective assessment from the Leeds Sleep Evaluation Questionnaire</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in the scores on the objective measurements of sleep architecture and patterns from polysomnography</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the scores on the SF(Short form)-35 quality of life questionnaire</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in safety parameters from the propofol infusion compared to baseline measured by laboratory markers, vital signs, electrocardiogram, pulse oximeter, physical exam and any adverse events</measure>
    <time_frame>5 days</time_frame>
    <description>Laboratory markers including complete blood count/chemistry values. Vital signs including blood pressure, pulse and temperature.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Insomnia</condition>
  <condition>Sleep Disorder</condition>
  <condition>Dyssomnia</condition>
  <arm_group>
    <arm_group_label>propofol infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol injectable emulsion</intervention_name>
    <arm_group_label>propofol infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, male or non-pregnant, non-lactating female, 18-65 years of age.

          -  Overall healthy with no other sleep disorder such as sleep apnea or periodic limb
             movement disorder

          -  Has not responded to conventional pharmacologic therapies (benzodiazepines and
             non-benzodiazepines) within the past 90 days. The non-benzodiazepine therapies can
             include melatonin and melatonin receptor agonists, antihistamines, antidepressants,
             over-the-counter medications, supplements or herbs for sleep

          -  Have refractory chronic primary insomnia (chronic-inadequate quantity or quality of
             sleep characterized by a subjective report of difficulty with sleep initiation,
             duration, consolidation, or quality that occurs despite adequate opportunity for
             sleep, and results in some form of daytime impairment and has persisted for at least
             one month., primary-insomnia independent of any known physical or mental condition,
             refractory-not yielding, at least not yielding readily to treatment based upon
             polysomnography at baseline, total sleep time (sTST) of &lt; 6 hr, a subjective wake time
             after sleep onset (WASO) of &gt;1 hr, a subjective latency to sleep onset (SOL) of &gt; 20
             min

          -  Willing and able to give written informed consent

          -  Clearly understands the procedures and requirements for the study

          -  Willing and able to comply with all study procedures and data recording obligations
             for the entire length of the study

          -  Have no clinically significant abnormalities on the basis of medical history, physical
             examination and vital signs in the judgment of the investigator and/or
             sub-investigator

          -  Ability and willingness to abstain from any pharmaceutical or over-the-counter
             medication for sleep as well as alcohol from 72 hours prior to baseline and the first
             dose until after completion of the Study Product Administration Follow-Up Visit (Day
             6) as well as 72 hours prior to the Day 90 visit.

          -  All values for hematology and for clinical chemistry tests of blood within the normal
             range for age and gender or showing no clinically relevant deviations as judged by the
             investigator

          -  Nonsmoking or have quit smoking at least 6 months prior to dosing

        Exclusion Criteria:

          -  Having any medical conditions including diabetes, cardiovascular disease, pulmonary,
             renal, endocrine, hepatic, neurologic, psychiatric (including depression),
             immunologic, hematologic, gastrointestinal or metabolic disease requiring medical
             treatment that would preclude participation into the study in the judgment of the
             investigator/sub-investigator

          -  Having ingested any pharmaceutical or over-the-counter sleep product within 72 hours
             of dosing as well as 72 hours prior to the Day 90 visit.

          -  Taking any medication that can yield a moderate to major drug interaction with
             propofol including those with CNS (central nervous system)-depressant effects

          -  Having had a history of any medical or surgical procedure that would preclude
             participation into the study in the judgment of the investigator/sub-investigator

          -  Being pregnant, planning on becoming pregnant, breast feeding or unwilling to use a
             medically acceptable form of birth control during the study (with at least one
             acceptable barrier for a period of one month prior to the beginning of the study until
             at least three months after study completion) or are surgically sterile or
             postmenopausal (at least 12 months without a period).

          -  Having a systolic blood pressure &gt;160 mmHg, diastolic blood pressure &gt;90 mmHg, or
             blood pressure that would preclude participation in the judgment of the
             investigator/sub-investigator

          -  Having a previous history of abnormal screening laboratory test values: bilirubin &gt; 2
             x ULN (upper limit of normal), AST(aspartate aminotransferase) and ALT (alanine
             aminotransferase) &gt; 2 x ULN (upper limit of normal), serum creatinine &gt; 1.5 mg/dl,
             fasting blood glucose below 85mg/dl or above 110 mg/dl, calcium level &lt; 8.6 mg/dl and
             triglycerides &gt;200.0mg/dl.

          -  Any type of active malignancy (except non-melanomatous skin malignancies) within the
             past 5 years

          -  History of known or suspected substance abuse

          -  Currently consume more than 7 standard alcoholic drinks per week and unable to refrain
             from consuming an alcoholic beverage during the course of the study dosing period.

          -  Currently consume more than 14 caffeinated beverages per week and unable to refrain
             from consuming a caffeinated beverage within 8 hours prior to dosing.

          -  History of allergy to any anesthetic, eggs, egg products, soybeans or soy products as
             well as hypersensitivity to Propofol or any of its components

          -  Unable to avoid engaging in a hazardous occupation requiring complete mental alertness
             and/or motor coordination after receiving the study product.

          -  Participation in another study within 30 days prior to dosing.

          -  Donated blood within 30 days prior to dosing.

          -  Illness within five days prior to dosing

          -  Having a pacemaker or any internal medical device

          -  In the opinion of the investigator, not suitable for entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A Czinn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesco North Broward LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Chest Physicians. Diagnosis and Treatment of Insomnia. http://chestnet.org/accp/pccsu/diagnosis-and-treatment-insomnia?page=0.3. Published September 3, 2007. Accessed February 6, 2012.</citation>
  </reference>
  <reference>
    <citation>Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer SL. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology. 2001 Aug;95(2):324-33.</citation>
    <PMID>11506101</PMID>
  </reference>
  <reference>
    <citation>http://www.drugs.com/pro/propofol</citation>
  </reference>
  <reference>
    <citation>http://www.drugs.com/mmx/propofol.html)</citation>
  </reference>
  <reference>
    <citation>Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002 Mar;51(3):229-35.</citation>
    <PMID>11978233</PMID>
  </reference>
  <reference>
    <citation>Mace AE. Sample-Size Determination. New York: Reinhold Publishing Corporation, 1964.</citation>
  </reference>
  <reference>
    <citation>Murphy M, Bruno MA, Riedner BA, Boveroux P, Noirhomme Q, Landsness EC, Brichant JF, Phillips C, Massimini M, Laureys S, Tononi G, Boly M. Propofol anesthesia and sleep: a high-density EEG study. Sleep. 2011 Mar 1;34(3):283-91A.</citation>
    <PMID>21358845</PMID>
  </reference>
  <reference>
    <citation>Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002 Apr;6(2):97-111.</citation>
    <PMID>12531146</PMID>
  </reference>
  <reference>
    <citation>Rabelo FA, Braga A, KÃ¼pper DS, De Oliveira JA, Lopes FM, de Lima Mattos PL, Barreto SG, Sander HH, Fernandes RM, Valera FC. Propofol-induced sleep: polysomnographic evaluation of patients with obstructive sleep apnea and controls. Otolaryngol Head Neck Surg. 2010 Feb;142(2):218-24. doi: 10.1016/j.otohns.2009.11.002.</citation>
    <PMID>20115978</PMID>
  </reference>
  <reference>
    <citation>Rajput V, Bromley SM. Chronic insomnia: a practical review. Am Fam Physician. 1999 Oct 1;60(5):1431-8; discussion 1441-2.</citation>
    <PMID>10524487</PMID>
  </reference>
  <reference>
    <citation>Ringdahl EN, Pereira SL, Delzell JE Jr. Treatment of primary insomnia. J Am Board Fam Pract. 2004 May-Jun;17(3):212-9. Review.</citation>
    <PMID>15226287</PMID>
  </reference>
  <reference>
    <citation>Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007 Aug 15;3(5 Suppl):S7-10. Review.</citation>
    <PMID>17824495</PMID>
  </reference>
  <reference>
    <citation>Saddichha S. Diagnosis and treatment of chronic insomnia. Ann Indian Acad Neurol. 2010 Apr;13(2):94-102. doi: 10.4103/0972-2327.64628.</citation>
    <PMID>20814491</PMID>
  </reference>
  <reference>
    <citation>Tung A, Bergmann BM, Herrera S, Cao D, Mendelson WB. Recovery from sleep deprivation occurs during propofol anesthesia. Anesthesiology. 2004 Jun;100(6):1419-26.</citation>
    <PMID>15166561</PMID>
  </reference>
  <reference>
    <citation>Tung A, Lynch JP, Mendelson WB. Prolonged sedation with propofol in the rat does not result in sleep deprivation. Anesth Analg. 2001 May;92(5):1232-6.</citation>
    <PMID>11323352</PMID>
  </reference>
  <reference>
    <citation>Vanlersberghe C, Camu F. Propofol. Handb Exp Pharmacol. 2008;(182):227-52. doi: 10.1007/978-3-540-74806-9_11. Review.</citation>
    <PMID>18175094</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Jiang X, Li W, Gao D, Li X, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys. 2011 Jul;60(3):161-6. doi: 10.1007/s12013-010-9135-7.</citation>
    <PMID>21107748</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleep disorder</keyword>
  <keyword>Sleep deprivation</keyword>
  <keyword>Chronic insomnia</keyword>
  <keyword>Refractory insomnia</keyword>
  <keyword>Primary insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

